Article Text

Download PDFPDF
Germ line and somatic mutations of BRAF V599E in ovarian carcinoma
  1. M. Ueda*,
  2. E. Toji* and
  3. S. Noda*
  1. *Cytopathology and Gynecology, Osaka Cancer Prevention and Detection Center, Osaka, Japan
  1. Address correspondence and reprint requests to: Masatsugu Ueda, MD, PhD, Cytopathology and Gynecology, Osaka Cancer Prevention and Detection Center, 1-6-107, Morinomiya, Joto-ku, Osaka 536-8588, Japan. Email: mueda{at}gan-osaka.or.jp

Abstract

It has been shown that ovarian low-grade serous carcinoma evolves out of a stepwise progression from benign serous cystadenoma to serous borderline tumor (SBT) to micropapillary serous carcinoma (MPSC), and that BRAF activation is a very early somatic event in the tumorigenesis. We postulated that BRAF could be a SBT susceptibility gene, and investigated both germ line and somatic mutations of BRAF V599E in 104 ovarian cancer patients. BRAF V599E mutation in histologic samples was found in 5 (24%) of 21 SBTs, 1 (33%) of 3 MPSCs, 1 (17%) of 6 endometrioid carcinomas, but not detected in 42 conventional serous carcinomas, 12 mucinous borderline tumors, 10 mucinous, and 10 clear-cell carcinomas. No V599E mutation could be detected in blood samples from these 104 patients. We also found no BRAF V599E mutation in 101 normal healthy women and 10 well-established ovarian cancer cell lines. Our results suggest that BRAF gene plays a “gatekeeper” role but does not act as a predisposition gene in the development of low-grade serous carcinomas

  • BRAF V599E
  • mutational analysis
  • ovarian tumorigenesis

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.